What companies make COVID vaccines?

Companies making COVID vaccines include: Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX), Moderna (NASDAQ:MRNA), and Novavax (NASDAQ:NVAX).

What is the future price of MRNA stock?

There's no way to predict the future price of Moderna (NASDAQ:MRNA) stock. However, the company has several promising candidates in its pipeline that could drive its share price higher over the next few years.

Pfizer (NYSE:PFE) is a publicly traded company owned by its shareholders. The drugmaker's largest shareholders include Vanguard Group, BlackRock (NYSE:BLK), and State Street (NYSE:STT).

Are vaccine stocks safe investments?

Vaccine stocks shouldn't be viewed as highly safe investments. These stocks can have significant risks, including clinical setbacks and regulatory failures. However, investors can mitigate the risks of investing in vaccine stocks by diversifying, focusing on established players with long track records of success, and maintaining a long-term mindset.

What is the most successful vaccine ever?

The smallpox vaccine is probably the most successful vaccine in history. Developed by Edward Jenner at the end of the 18th century, this vaccine eventually eradicated the smallpox virus that had killed hundreds of millions of people in the past.

Are vaccine stocks considered high-risk or high-reward investments?

Some vaccine stocks, especially smaller ones, are high-risk/potentially high-reward investments. Larger vaccine stocks tend to be less risky.

6 Best Vaccine Stocks for 2026 and How to Invest

Learn about the companies that are manufacturing vaccines and what you should know before investing in vaccine stocks.

By Keith Speights – Updated Jul 13, 2026 at 10:47 AM EST | Fact-checked by Frank Bass

Key Points

Pfizer remains buoyant with vaccines for pneumococcal disease and RSV, despite falling COVID-19 vaccine sales.
BioNTech, notable for its mRNA technology, eyes future growth with new vaccine candidates.
Moderna and GSK diversify with approvals for RSV and shingles vaccines, respectively, enhancing stability.

Vaccine stocks are shares of publicly traded companies involved in developing vaccines that immunize against many disease-causing microorganisms. While vaccine stocks performed especially well during the COVID-19 pandemic, sales of COVID-19 vaccines have plunged in recent years. Does that mean investors should throw in the towel on vaccine stocks? Not at all.

For one thing, COVID-19 vaccines continue to generate significant revenue despite the sales declines. More importantly, there are lots of other types of vaccines that are key growth drivers for some pharmaceutical companies.

Here's what you need to know about investing in the top vaccine stocks, along with our top vaccine stock picks.

Loading paragraph...

Top vaccine stocks to consider

Here are four top vaccine stocks, plus two others to watch:

Ticker Information Table
Name and ticker	Market capMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.	Current price	Dividend yield
Pfizer (NYSE:PFE)	$139.5 billion	$24.22	7.03%
BioNTech Se (NASDAQ:BNTX)	$22.8 billion	$90.75	0.00%
Moderna (NASDAQ:MRNA)	$26.6 billion	$67.21	0.00%
GSK (NYSE:GSK)	$104.7 billion	$51.28	3.43%
Bavarian Nordic A/s (OTC:BVNRY)	$2.1 billion	$9.28	0.00%
Emergent BioSolutions (NYSE:EBS)	$413.3 million	$7.49	0.00%

Data as of Jul 14, 2026. Showing 6 of 6 total entries.

Loading ticker_table...

1. Pfizer

NYSE: PFE

Pfizer

Today's Change

(-1.06%) $-0.26

Current Price

$24.22

Key Data Points

Market Cap

$140B

Day's Range

$24.14 - $24.42

52wk Range

$23.11 - $28.75

Volume

606.6K

Avg Vol

40.2M

Gross Margin

65.16%

Dividend Yield

7.03%

Loading company_card...

Pfizer (PFE -1.00%) made a great decision in 2020 when it partnered with the German biotechnology company BioNTech (BNTX +0.57%) to develop a COVID-19 vaccine. The vaccine, branded Comirnaty, was the first to win U.S. approval and was a massive commercial success for Pfizer -- at least for a few years.

Dwindling sales for Comirnaty have caused Pfizer's revenue to sink and have taken a steep toll on the pharmaceutical company's stock. However, Pfizer has two other vaccines on the market that generate significant revenue: pneumococcal vaccine Prevnar 20 and respiratory syncytial virus (RSV) vaccine Abrysvo.

Pfizer's pipeline features several other vaccines under development. They include Lyme disease vaccine PF-07307405, streptococcus vaccine PF-06760805, and influenza vaccine PF-07252220.

Vaccines aren't the only products that could contribute to Pfizer's growth, though. The company also markets drugs that treat a wide variety of conditions, including autoimmune diseases, cancer, and migraine. In addition, Pfizer pays an attractive dividend, making the stock a favorite of income-seeking investors.

2. BioNTech

Loading paragraph...

NASDAQ: BNTX

BioNTech Se

Today's Change

(0.76%) $0.68

Current Price

$90.75

Key Data Points

Market Cap

$23B

Day's Range

$88.61 - $91.20

52wk Range

$79.52 - $124.00

Volume

15.5K

Avg Vol

954K

Gross Margin

73.25%

Loading company_card...

As Pfizer's partner, BioNTech (BNTX +0.57%) benefited from Pfizer's financial resources, global manufacturing capacity, and regulatory expertise. The company's messenger RNA (mRNA) technology was critical to the success of the COVID-19 vaccine it developed jointly.

This COVID-19 vaccine remains BioNTech's primary revenue source for now. However, the company is working with Pfizer to evaluate a combination COVID-19/flu vaccine.

BioNTech is also developing several other vaccines and therapies targeting various types of cancer. Some of these programs are based on mRNA technology, while others are protein-based therapeutics.

One thing to watch with BioNTech, though, is that its co-founders, Ugur Sahin and Özlem Türeci, plan to leave the company to start a new, independent biotech company. Sahin currently serves as BioNTech's CEO.

3. Moderna

Loading paragraph...

NASDAQ: MRNA

Moderna

Today's Change

(0.29%) $0.20

Current Price

$67.21

Key Data Points

Market Cap

$27B

Day's Range

$65.80 - $67.87

52wk Range

$22.28 - $85.60

Volume

140.8K

Avg Vol

7.9M

Gross Margin

11.55%

Loading company_card...

Moderna (MRNA +0.84%) quickly followed Pfizer and BioNTech in winning U.S. approval for its COVID-19 vaccine. Although sales for this vaccine, marketed under the brand name SpikeVax, have deteriorated, it remains a major source of revenue for the company.

SpikeVax is no longer Moderna's only approved product, though. The company won U.S. approval in May 2024 for its RSV vaccine, mResvia, and its next-generation COVID-19 vaccine NEXSPIKE in 2025. It also received European approval in April 2026 for mCOMBRIAX, the first flu/COVID-19 combination vaccine.

Moderna could have additional new products on the way. It awaits U.S. approval of seasonal flu vaccine mRNA-1010. The company is working with Merck (MRK -2.66%) in the late-stage development of cancer vaccine mRNA-4157. Its pipeline also includes experimental vaccines and therapies in phase 1 and phase 2 testing that target several viruses and rare diseases.

Loading paragraph...

4. GSK

NYSE: GSK

GSK

Today's Change

(-1.94%) $-1.02

Current Price

$51.28

Key Data Points

Market Cap

$105B

Day's Range

$51.06 - $51.93

52wk Range

$35.45 - $61.70

Volume

130.4K

Avg Vol

3.8M

Gross Margin

72.81%

Dividend Yield

3.43%

Loading company_card...

GSK (GSK -1.86%) wasn't a major player in the COVID-19 vaccine market. However, the big pharmaceutical company has 17 other approved vaccines, including Shingrix, a shingles vaccine.

Like Pfizer and Moderna, GSK markets an RSV vaccine for adults. The company won U.S. approval for the vaccine, which has the brand name Arexvy, in May 2023 for immunizing older adults and in June 2024 for adults ages 50 through 59.

GSK won U.S regulatory approval in February 2025 for meningitis vaccine Penmenvy. It is also evaluating several vaccines in late-stage clinical trials.

Vaccines aren't GSK's only focus, though. The drugmaker also markets medications targeting cancer as well as cardiovascular, neurological, and respiratory diseases.

Loading paragraph...

Other vaccine stocks to watch

Pfizer, BioNTech, Moderna, and GSK are arguably the top vaccine stocks for investors to consider. However, there are at least two other vaccine stocks to watch.

Bavarian Nordic A/S (OTC:BVNR.Y) markets vaccines for tick-borne encephalitis, smallpox, mpox (also known as monkeypox), rabies, cholera, and typhoid. An mpox outbreak in 2024 put this stock on the map for some investors.

Loading paragraph...

OTC: BVNRY

Bavarian Nordic A/s

Today's Change

(1.53%) $0.14

Current Price

$9.28

Key Data Points

Market Cap

$2.1B

Day's Range

$9.28 - $9.41

52wk Range

$8.67 - $13.00

Volume

2.6K

Avg Vol

3.8K

Gross Margin

46.99%

Loading company_card...

Emergent Biosolutions (EBS -6.49%) is probably best known for its anthrax vaccines and Narcan nasal spray for the emergency treatment of opioid overdoses. However, the company also markets other products, including smallpox and mpox vaccine ACAM2000.

Loading paragraph...

NYSE: EBS

Emergent BioSolutions

Today's Change

(-6.49%) $-0.52

Current Price

$7.49

Key Data Points

Market Cap

$413M

Day's Range

$7.39 - $8.01

52wk Range

$5.62 - $14.06

Volume

852.1K

Avg Vol

815.5K

Gross Margin

44.44%

Loading company_card...

How to buy vaccine stocks

Follow these steps to invest in vaccine stocks:

Open your brokerage app: Log in to your brokerage account where you handle your investments. If you don't have one yet, take a look at our favorite brokers and trading platforms to find the right one for you.
Search for the stock: Enter the ticker or company name into the search bar to bring up the stock's trading page.
Decide how many shares to buy: Consider your investment goals and how much of your portfolio you want to allocate to this stock.
Select order type: Choose between a market order to buy at the current price or a limit order to specify the maximum price you're willing to pay.
Submit your order: Confirm the details and submit your buy order.
Review your purchase: Check your portfolio to ensure your order was filled as expected and adjust your investment strategy accordingly.

Loading paragraph...

Benefits and risks of investing in vaccine stocks

The benefits of investing in vaccine stocks include:

Growth opportunities with the shift from pandemic revenue to more predictable revenue from vaccines targeting viruses with recurring immunization cycles, such as flu and RSV.
Pipeline optionality, especially with several vaccine makers expanding beyond infectious diseases into vaccines that target cancer.
Several vaccine stocks currently offer attractive valuations.
Vaccine stocks often enjoy steadier, less cyclical demand, helping investors insulate their portfolios during broad market downturns.

However, there are also several risks associated with investing in vaccine stocks, such as:

Declining revenue from COVID-19 vaccines.
Potential for clinical trial failures.
Possibility of regulatory setbacks.
Changes to government policies on recommendations could affect vaccine sales.

Loading paragraph...

Methodology: How these stocks were chosen

The obvious -- and most important -- criterion in selecting these stocks was that they all had to develop vaccines. These particular stocks were selected because their vaccines are highly competitive.

Preference was given to the stocks of companies that already have approved products. These vaccine makers generate revenue. Some are already profitable.

Growth prospects were also considered. Each of the four primary vaccine stocks selected should have solid growth potential. The two vaccine stocks to watch (Bavarian Nordic and Emergent Biosolutions) could also deliver strong growth, but are riskier than the others.

Loading paragraph...

Should you invest in vaccine stocks?

Probably the most important characteristic of investors who could find vaccine stocks attractive is that they're comfortable with volatility. If you can't handle wild stock swings resulting from clinical updates or regulatory announcements, you'll probably be better off looking elsewhere.

Your investing horizon is another key factor in determining if vaccine stocks are for you. Vaccines can take years to develop and reach the market. As a result, vaccine stocks will be a better fit for investors with long-term horizons of at least five to 10 years.

Some investors whose portfolios are heavily weighted toward stable, defensive holdings could also find it appealing to buy small stakes in vaccine stocks. In addition, larger vaccine makers that pay dividends, such as Pfizer and GSK, could be attractive to income investors.

Loading paragraph...

FAQ

Vaccine stocks FAQ

Loading faq...

About the Author

Keith Speights is a contributing Motley Fool healthcare analyst covering publicly traded companies across pharmaceuticals, biotechnology, medical devices, technology, and marijuana. Prior to The Motley Fool, Keith was CEO of Constant Care Technology, a healthcare technology company; vice president of American HealthTech, a healthcare software company; and a director of operations for Blue Cross Blue Shield of Mississippi, a health insurer. He holds a B.S. in Industrial Engineering from Mississippi State University.

TMFFishBiz

Keith Speights has positions in Pfizer. The Motley Fool has positions in and recommends Merck, Moderna, and Pfizer. The Motley Fool recommends BioNTech Se, Emergent BioSolutions, and GSK. The Motley Fool has a disclosure policy.

6 Best Vaccine Stocks for 2026 and How to Invest

Learn about the companies that are manufacturing vaccines and what you should know before investing in vaccine stocks.

Key Points

Top vaccine stocks to consider

1. Pfizer

Key Data Points

2. BioNTech

Key Data Points

3. Moderna

Key Data Points

4. GSK

Key Data Points

Other vaccine stocks to watch

Key Data Points

Key Data Points

How to buy vaccine stocks

Benefits and risks of investing in vaccine stocks

Methodology: How these stocks were chosen

Should you invest in vaccine stocks?

Related investing topics

6 Best Healthcare Stocks for 2026 and How to Invest

Biotech vs. Pharma: What's the Difference?

Pharmaceutical tariffs: Which countries does the U.S. import the most from?

5 Best Biotech Stocks for 2026 and How to Invest

FAQ

Vaccine stocks FAQ

What companies make COVID vaccines?

What companies make COVID vaccines?

What is the future price of MRNA stock?

What is the future price of MRNA stock?

Who owns Pfizer?

Who owns Pfizer?

Are vaccine stocks safe investments?

Are vaccine stocks safe investments?

What is the most successful vaccine ever?

What is the most successful vaccine ever?

Are vaccine stocks considered high-risk or high-reward investments?

Are vaccine stocks considered high-risk or high-reward investments?

About the Author

Stocks Mentioned

Motley Fool Stock Advisor’s Latest Pick

Premium Investing Services

Key Data Points

Key Data Points

Key Data Points

Key Data Points

Key Data Points

Key Data Points

How to buy vaccine stocks

Benefits and risks of investing in vaccine stocks

Methodology: How these stocks were chosen

Should you invest in vaccine stocks?

6 Best Healthcare Stocks for 2026 and How to Invest

Biotech vs. Pharma: What's the Difference?

Pharmaceutical tariffs: Which countries does the U.S. import the most from?

5 Best Biotech Stocks for 2026 and How to Invest

Vaccine stocks FAQ

What companies make COVID vaccines?

What companies make COVID vaccines?

What is the future price of MRNA stock?

What is the future price of MRNA stock?

Who owns Pfizer?

Who owns Pfizer?

Are vaccine stocks safe investments?

Are vaccine stocks safe investments?

What is the most successful vaccine ever?

What is the most successful vaccine ever?

Are vaccine stocks considered high-risk or high-reward investments?

Are vaccine stocks considered high-risk or high-reward investments?

2. BioNTech

3. Moderna

Other vaccine stocks to watch